A carregar...

Antibodies and Tyrosine Kinase Inhibitors in Breast Cancer Therapies

In recent years, new classes of molecules have been established as opportunities for the treatment of breast cancer. The approval of trastuzumab, the antibody against Her2/neu, in the late 1990s was followed by the approval of the antiangiogenic antibody bevacizumab in 2007. Progress in the understa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Barth, J., Jackisch, Christian, Untch, Michael
Formato: Artigo
Idioma:Inglês
Publicado em: S. Karger GmbH 2009
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2942015/
https://ncbi.nlm.nih.gov/pubmed/21160542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000190063
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!